Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LSS | P48449 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5787700 | 1.00 | HRH3 (0.60) | HRH3ALDH1A1LSSHRH4KDM4E | |
| SCHEMBL5791470 | 0.84 | HRH3 (0.59) | HRH3ALDH1A1LSSHRH4KDM4E | |
| SCHEMBL5802543 | 0.84 | HRH3 (0.47) | HRH3ALDH1A1MEN1KMT2A | |
| SCHEMBL6095321 | 0.84 | HRH3 (0.47) | HRH3ALDH1A1MEN1KMT2A | |
| SCHEMBL5802540 | 0.84 | HRH3 (0.47) | HRH3ALDH1A1MEN1KMT2A | |
| SCHEMBL5803369 | 0.80 | HRH3 (0.54) | HRH3ALDH1A1LSSHRH4KDM4E | |
| SCHEMBL5803366 | 0.80 | HRH3 (0.54) | HRH3ALDH1A1LSSHRH4KDM4E | |
| SCHEMBL5790533 | 0.79 | HRH3 (0.56) | HRH3ALDH1A1HRH4KDM4EMEN1 | |
| SCHEMBL5790534 | 0.79 | HRH3 (0.56) | HRH3ALDH1A1HRH4KDM4EMEN1 | |
| SCHEMBL5785931 | 0.79 | HRH3 (0.51) | HRH3ALDH1A1LSSHRH4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720847-A1 | HISTAMINE-3 RECEPTOR MODULATORS | Pfizer Products Incorporated (US) | 2006-11-15 | — | — | EP | claimed |
| US-7115600-B2 | Histamine-3 receptor modulators | PFIZER INC. (US) | 2006-10-03 | — | — | US | claimed |
| WO-2005080361-A1 | HISTAMINE-3 RECEPTOR MODULATORS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | PFIZER INC | 2005-08-04 | — | — | US | claimed |
| EP-1720847-A1 | HISTAMINE-3 RECEPTOR MODULATORS | Pfizer Products Incorporated (US) | 2006-11-15 | — | — | EP | disclosed |
| US-7115600-B2 | Histamine-3 receptor modulators | PFIZER INC. (US) | 2006-10-03 | — | — | US | disclosed |
| WO-2005080361-A1 | HISTAMINE-3 RECEPTOR MODULATORS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | HRH3, HRH4, HRH1 | HRH3 1/4885ALDH1A1 927/4885LSS 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.